Australia's most trusted
source of pharma news
Wednesday, 10 December 2025
Posted 8 December 2025 AM
A $48 million PBS-listed diabetes drug has seen the first hint of a challenge with the first generic hitting the ARTG.
Boehringer Ingelheim is looking over its shoulder, with Alphapharm registering the first generic for Boehringer's type 2 diabetes drug Trajenta. The new brand, Linagliptin Viatris, has the same indication of adult patients with type 2 diabetes to improve glycaemic control in conjunction with diet and exercise, as a monotherapy or in combination.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.